Zhu Z, Ghose T, Lee S H, Fernandez L A, Kerr L A, Donohue J H, McKean D J
Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Cancer Lett. 1994 Oct 28;86(1):127-34. doi: 10.1016/0304-3835(94)90189-9.
A heteroconjugate (HC) antibody, constructed with the monoclonal antibody (MoAB) Dal K29 to human renal cell carcinoma (RCC) and an anti-CD3 MoAb, could induce a very high level of lysis of human RCC cells when incubated with human peripheral blood lymphocytes (PBL) in vitro (Kerr et al., 1990, J. Immunol., 144, 4060-4067). We now report that this HC antibody selectively localizes in RCC xenografts in nude mice and could inhibit RCC in an ascites tumor xenograft model when administered intraperitoneally together with PBL.
一种异源共轭（HC）抗体，由针对人肾细胞癌（RCC）的单克隆抗体（MoAB）Dal K29和抗CD3单克隆抗体制备而成，当在体外与人外周血淋巴细胞（PBL）一起孵育时，可诱导对人肾癌细胞的高水平裂解（Kerr等人，1990年，《免疫学杂志》，144卷，4060 - 4067页）。我们现在报告，这种HC抗体在裸鼠的RCC异种移植瘤中选择性定位，并且当与PBL一起腹腔注射时，在腹水肿瘤异种移植模型中可抑制RCC。
